XTL Biopharmaceuticals Ltd. (XTLB) EPS by Year
XTL Biopharmaceuticals Ltd. lost $0.00 per diluted share in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. The table below carries 11 fiscal years, from 2015 to 2025, and the quarters XTL Biopharmaceuticals Ltd. has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
XTLB EPS (Diluted) by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
XTLB EPS (Diluted) by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
XTLB files its annual report on Form 20-F and its quarterly results on Form 6-K, and SEC's XBRL data holds no figures from those 6-K reports, so the quarterly figures here stop at the quarter ended December 31, 2024, while the annual figures run through FY2025.
What diluted earnings per share means
Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.